Skip to Main Content
A service of the U.S. National Institutes of Health
Example: "Heart attack" AND "Los Angeles"
Search for studies:
Advanced Search
Help
Studies by Topic
Glossary
Find Studies
Basic Search
Advanced Search
See Studies by Topic
See Studies on a Map
How to Search
How to Use Search Results
How to Find Results of Studies
How to Read a Study Record
About Clinical Studies
Learn About Clinical Studies
Other Sites About Clinical Studies
Glossary of Common Site Terms
Submit Studies
Why Should I Register and Submit Results?
FDAAA 801 Requirements
How to Apply for an Account
How to Register Your Study
How to Edit Your Study Record
How to Submit Your Results
Frequently Asked Questions
Support Materials
Training Materials
Resources
Selected Publications
Clinical Alerts and Advisories
RSS Feeds
Trends, Charts, and Maps
Downloading Content for Analysis
About This Site
ClinicalTrials.gov Background
About the Results Database
History, Policies, and Laws
Media/Press Resources
Linking to This Site
Terms and Conditions
Disclaimer
Text Size
Make bigger
Make smaller
Reset
close
Home
Find Studies
Search Results
264 studies found for
: "Emtricitabine"[TREATMENT] AND HIV [CONDITION]
Modify this search
|
How to Use Search Results
List
By Topic
On a Map
Search Details
Show Display Options
Subscribe to RSS
Create an RSS feed from your search for:
"Emtricitabine"[TREATMENT] AND HIV [CONDITION]
Need help? See
RSS Feeds
Choose a feed type:
Show studies that were
first received
in the last 14 days
Show studies that were
added
or
modified
in the last 14 days
Cancel
Download
Download the search results for:
"Emtricitabine"[TREATMENT] AND HIV [CONDITION] (264 records)
Need help? See
Downloading Content for Analysis
Number of Studies:
Top 10 Studies
Top 100 Studies
20 Shown Studies
264 Found Studies
Download Content:
Download All Study Fields as XML
Download All Study and Results Fields as XML
Download Selected Fields:
Select fields:
2 Shown Fields
21 Available Fields
Select field format:
Plain text
Tab-separated values
Comma-separated Values
XML
Zip file readers with free trial periods:
WinZip
or
PKZip
Cancel
Display Options
Study Details
Condition
Intervention
Study Type
Phase
Sponsor/Collaborators
Funder Type
Study Design
Outcome Measures
Participant Details
Number Enrolled
Gender
Age Group
Identifiers
NCT Number
Other IDs
Title Acronym
Dates
Study Start
Primary Completion
Study Completion
First Received
Last Updated
Last Verified
Results First Received
Cancel
Include only
open studies
Exclude studies with
unknown status
Rank
Status
Study
1
Recruiting
Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions:
HIV; HIV Infections
Interventions:
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
2
Recruiting
Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults
Conditions:
HIV; HIV Infections
Interventions:
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
3
Recruiting
Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women
Conditions:
Acquired Immunodeficiency Syndrome; HIV Infections
Interventions:
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
4
Active, not recruiting
Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Conditions:
Acquired Immunodeficiency Syndrome; HIV Infections
Interventions:
Drug: elvitegravir/cobicistat/emtricitabine/GS-7340; Drug: elvitegravir/cobicistat/emtricitabine/ tenofovir df
5
Active, not recruiting
Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Conditions:
Acquired Immunodeficiency Syndrome; HIV Infections
Interventions:
Drug: darunavir/cobicistat/emtricitabine/GS-7340; Drug: darunavir + cobicistat + emtricitabine/tenofovir df
6
Active, not recruiting
Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Conditions:
HIV; HIV Infections
Interventions:
Drug: GS-9350 + atazanavir + emtricitabine/tenofovir DF; Drug: Comparator: ritonavir + atazanavir + emtricitabine/tenofovir DF
7
Active, not recruiting
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions:
Acquired Immunodeficiency Syndrome; HIV Infections
Interventions:
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
8
Active, not recruiting
Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions:
Acquired Immunodeficiency Syndrome; HIV Infections
Interventions:
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
9
Active, not recruiting
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions:
Acquired Immunodeficiency Syndrome; HIV Infections
Intervention:
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
10
Recruiting
Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Conditions:
HIV; HIV Infections
Intervention:
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
11
Not yet recruiting
Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Conditions:
HIV; HIV Infections
Interventions:
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or GS-9350 + atazanavir + FTC/TDF
12
Withdrawn
Raltegravir Activity In Lymphoid Tissues
Conditions:
HIV Infection; HIV Infections
Interventions:
Drug: Efavirenz + Tenofovir DF/Emtricitabine; Drug: Raltegravir + Tenofovir DF/Emtricitabine; Procedure: Colonoscopy with biopsies; Procedure: Inguinal Lymph Node Excision
13
Recruiting
Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Conditions:
Acquired Immunodeficiency Syndrome; HIV Infections
Intervention:
Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
14
Completed
An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
Condition:
HIV Infections
Intervention:
Drug: Emtricitabine
15
Recruiting
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Conditions:
HIV; HIV Infections
Interventions:
Drug: emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line); Drug: abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line); Drug: emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
16
Completed
Has Results
ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens
Condition:
Human Immunodeficiency Virus (HIV)
Interventions:
Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz); Drug: Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV); Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
17
Recruiting
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Condition:
HIV Infection
Interventions:
Drug: Tenofovir, Emtricitabine, Lopinavir/r; Drug: Tenofovir, Emtricitabine, Raltegravir
18
Active, not recruiting
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
Condition:
HIV-1 Infection
Interventions:
Drug: emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate
19
Completed
PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
Conditions:
HIV Infection; HIV Infections
Intervention:
Drug: Atripla®
20
Unknown
†
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
Condition:
HIV Infections
Interventions:
Drug: Raltegravir; Drug: Maraviroc; Drug: Tenofovir/Emtricitabine
To Top
Previous Page
Studies Shown (1-20)
Next Page (21-40)
†
Indicates status has not been verified in more than two years
To Top
Copyright
Privacy
Accessibility
Viewers & Players
Freedom of Information Act
USA.gov
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services